GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Inventories, Inventories Adjustments

Chimeric Therapeutics (ASX:CHM) Inventories, Inventories Adjustments : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Inventories, Inventories Adjustments?

Chimeric Therapeutics's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Chimeric Therapeutics Inventories, Inventories Adjustments Historical Data

The historical data trend for Chimeric Therapeutics's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Inventories, Inventories Adjustments Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Inventories, Inventories Adjustments
- - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Inventories Adjustments Get a 7-Day Free Trial - - - - -

Chimeric Therapeutics Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Chimeric Therapeutics (ASX:CHM) Business Description

Industry
Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines